

























































published: 18 December 2013
doi: 10.3389/fendo.2013.00194
Stressed liver and muscle call on adipocytes with FGF21
Yongde Luo* andWallace L. McKeehan
IBT Proteomics and Nanotechnology Laboratory, Center for Cancer and Stem Cell Biology, Institute of Biosciences andTechnology, Texas A&M Health Science
Center, Houston, TX, USA
Edited by:
Gary Sweeney, Institut Pasteur, South
Korea, York University, Canada
Reviewed by:
Minho Shong, Research Center for
Endocrine and Metabolic Diseases,
South Korea
StephanWueest, University
Children’s Hospital Zurich, Switzerland
*Correspondence:
Yongde Luo, IBT Proteomics and
Nanotechnology Laboratory, Center
for Cancer and Stem Cell Biology,
Institute of Biosciences and
Technology, Texas A&M Health
Science Center, 2121W. Holcombe
Blvd., Houston, TX 77030-3303, USA
e-mail: yluo@ibt.tamhsc.edu
Fibroblast growth factor 21 (FGF21) is an emerging regulator of local and systemic meta-
bolic homeostasis. Treatment with pharmacological levels of FGF21 alleviates obesity
and associated metabolic diseases including diabetes. However, beyond anti-obesogenic
effects, the normal roles and underlying mechanisms of FGF21 as an endocrine hor-
mone remain unclear. A recent wave of studies has revealed that FGF21 is a stress-
induced endocrine factor in liver, muscle, and other tissues that targets adipose tissue and
adipocytes through the FGFR1-betaKlotho complex. Adipose tissues and adipocytes within
diverse tissues respond with metabolites and adipokine signals that affect functions of body
tissues systemically and cells within the local microenvironment adjacent to adipocytes.
Normally this is to prevent impaired tissue-specific function and damage to diverse tissues
secreting FGF21 in response to chronic stress. Therefore, diverse stressed tissues and
the adipose tissue and adipocytes constitute a beneficial endocrine and paracrine com-
munication network through FGF21. Here we attempt to unify these developments with
beneficial pharmacological effects of FGF21 on obesity in respect to inter-organ stress
communication and mechanisms.
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INTRODUCTION
ENDOCRINE FGFS AND THE ROLE OF FGF21
Since the debut in 2005 (1), fibroblast growth factor 21 (FGF21)
has been of growing interest due to its dramatic beneficial effects
at pharmacological levels on weight reduction and alleviation of
obesity, diabetes, and fatty liver disease (2, 3). These effects include
promoting clearance of systemic glucose and lipids (cholesterol,
fatty acids, and triacylglycerides) and enhancing insulin sensitiv-
ity, adiponectin action, mitochondrial function, thermogenesis,
and energy expenditure (1, 2, 4). Unlike most of the FGF family
members that require extracellular heparan sulfate proteoglycan
and act locally via autocrine and paracrine mechanisms, FGF21
as a member of the endocrine FGF19 subfamily travels through
the circulation to sites distal from its origin and acts predom-
inantly as an endocrine hormone (5). Instead of heparan sulfate
proteoglycans, the activity of FGF21 is determined by a transmem-
brane co-receptor betaKlotho (KLB) that is present as a binary
complex with FGF receptor tyrosine kinases (FGFR) in several
endocrine and metabolic tissues. This allows selective action of
circulating FGF21 on the target tissues expressing FGFR1-KLB
complex without affecting those expressing FGFR1 alone.
Basal serum levels of FGF21 vary widely among individuals and
are generally low in pure strains of laboratory mice (6). Deficiency
or overexpression of FGF21 does elicit alterations in metabolic
gene expression in the liver and adipose tissue, but without dra-
matic metabolic phenotypes under normal physiological condi-
tions (7, 8). In contrast, pharmacologic applications of FGF21 in
obese and diabetic animals suggest a wide range of effects across
multiple tissues with marked anti-obesogenic and anti-diabetic
efficacy (1, 2, 4, 9). However, beyond such drastic pharmaco-
logical effects in the obese, the possible functions of FGF21 as
a circulating hormone in organ-specific physiopathologies have
remained elusive.
FGF21 AS AN INDUCIBLE STRESS HORMONE FROMMULTIPLE TISSUES
Studies in mice indicate that FGF21 is inducible and the liver is
a major source of circulating FGF21 (9, 10). Parallel to serum
levels, expression of hepatic FGF21 under normal physiological
conditions is low; however, during prolonged fasting and starva-
tion,both hepatic and serum FGF21 become dramatically elevated.
This triggered early proposals that the physiological role of FGF21
was a starvation hormone that regulates ketogenesis essential for
brain function during severe carbohydrate deficits (9, 10). A grow-
ing number of studies with animals and patients indicate that
FGF21 is induced, in addition to starvation and obesity, by diverse
pathogenic conditions such as liver injury, viral infection, chemi-
cal insult, specific nutritional deficiency, the hepatic regenerative
response as well as liver diseases as hepatosteatosis, steatohepati-
tis, cirrhosis, and liver cancer (11–17). The common feature of all
these conditions is that they impose stress on the liver that compro-
mises its role in maintenance of organism metabolic homeostasis.
Therefore, hepatic FGF21 appears to be an inducible hepatic stress
signal.
In contrast to the liver that is a switching station for processing
metabolites in support of other organs and tissues and the adi-
pose tissue that serves as a storage depot of energy and metabolic
precursor of lipids, muscle is a major fuel consumer. To meet high
aerobic catabolic demands for ATP, muscle secretes myokines that
call on liver and adipose tissue to supply adequate fuel. Consis-
tent with this concept, several recent studies indicate that FGF21 is
induced in skeletal, heart, and gastrocnemius muscle under condi-
tions that cause local and systemic metabolic stress (18–25). These
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include patients with a mitochondrial respiratory chain deficiency
in myocytes and mice defective in muscular autophagy/mitophagy
(20, 26, 27). FGF21 may be an insulin and AKT-regulated myokine
and its expression is associated with chronic muscular hyperinsu-
linemia or lipodystrophy (22, 23). Increases in muscle contraction
such as in chronic exercise also upregulates muscular FGF21 pro-
duction (21, 25). Fe-S cluster-deficient muscles in patients showed
a dramatic upregulation of FGF21 expression and elevated levels
of circulating FGF21 (20). This indicates that muscle stressed by
perturbations in mitochondrial energy metabolism responds by
increasing the secretion of FGF21 into the circulation.
In addition to liver and muscle, it has been suggested that
FGF21 is inducible and secreted into the circulation in other tissues
and organs under stress conditions. Brown adipose tissue (BAT)
may be a source of FGF21 in response to cold stress and fetal-to-
neonatal transition (28, 29). White adipose tissue (WAT) has been
reported to secrete FGF21 under some conditions (30). However,
a physiological contribution of stress-induced adipocyte FGF21
to systemic FGF21, or an autocrine activity of FGF21 within WAT,
BAT, and adipocytes in the local microenvironment, remains to
be validated. Since stressed pancreas has been reported to be a
beneficiary of external FGF21 (31, 32), it is also a candidate for
induction of FGF21 as a signal for aid from adipose tissue.
These studies suggests that the activation of FGF21 in liver,
muscle, and other tissues is a response of these tissues and organs
to stress triggered by external challenge and internal cellular patho-
genesis that lead to defects in metabolic homeostasis. In support
of this notion, several nuclear receptors and transcription factors
that are involved in metabolic stress responses regulate FGF21
expression. These include PPARα/γ, RAR, ChREBP, SREBP1c,
LXR, STAT3/5, p53, and ATF4 (9, 16, 26, 33–39). The question
is why these organs when under stress use FGF21 as a systemic
alarm signal.
ADIPOCYTES ARE THE TARGET OF FGF21 FROMMULTIPLE TISSUES
Several recent studies using direct ablation of FGFR1 or KLB in
adipocytes, administration of activating antibody targeting specif-
ically the FGFR1-KLB complex, or induction of dysfunctional
adipose tissue (40–44) provide compelling evidence that adipose
tissue and adipocyte FGFR1-KLB is the primary tissue and molec-
ular target of inter-organ messenger FGF21, respectively. Although
many types of tissues and cells express FGFR1 alone, mature
adipocytes co-express FGFR1 with KLB, the transmembrane co-
receptor for FGF21 and FGF19 (45). Similar to the general abla-
tion of FGF21 (8), adipocyte-specific FGFR1 ablation resulted
in few overt changes in adipogenesis, adipose secretory function,
and systemic metabolic status under normal physiological condi-
tions (46). However, under the metabolic stress of starvation, the
absence of adipocyte FGFR1 caused increased adipocyte lipolysis.
This occurred concurrently with elevation of serum triglycerides
and fatty acids while indirectly causing an increase in hepatic
lipogenesis and steatosis (46). This indicated that under such
conditions adipocyte FGFR1 signaling dampens adipocyte lipoly-
sis while concurrently dampening hepatic steatosis. Paradoxically
yet most dramatically, the adipocyte FGFR1 deficiency abrogated
nearly all the anti-obese and anti-diabetic effects elicited by phar-
macological levels of FGF21 (40, 43). The alleviation of muscular
abnormalities caused by muscular mitochondrial energy dysfunc-
tion and defects in autophagy/mitophagy appear to be in large part
due to effects of induced FGF21 on adipose tissue (26, 27). Adap-
tation to cold stress may be aided by elevated levels of FGF21 that
acts on BAT to promote pro-thermogenic mitochondrial activity
(28, 29).
Taken together, these studies indicate that stress messenger
FGF21 and adipose FGFR1-KLB team up to respond to stress
caused by a wide range of metabolic abnormalities and patho-
genesis. The stress-responsive communication mediated by extra-
adipose FGF21 and adipocyte FGFR1-KLB occurs predominantly
between adipose tissue and at least two tissues whose roles in
metabolism are quite different, but when stressed have major con-
sequences on the organism: (1) liver whose role is to maintain lipid,
carbohydrate, and organism metabolic homeostasis through syn-
thesis, degradation, and temporary storage; and (2) muscle which
is a major fuel consumer predominantly powered by the oxida-
tion of fats and carbohydrates (Figure 1). Although so far liver
and muscle have received the most attention as two major organs
that send out FGF21 as a stress signal, other organs may utilize
the same mechanism to call on adipocytes in major fat depots
(WAT and BAT) or in the microenvironment of diverse tissues.
Within the microenvironment of tissues that contains ectopic or
interspersed adipose tissue or adipocytes, such as the breast, bone
marrow, and the perirenal and epicardial regions, FGF21 may serve
to modify adipocyte signaling that affects parenchymal cell func-
tions through a paracrine mechanism. Within stressed adipose
tissues which are predominantly adipocytes, both paracrine and
autocrine mechanisms may be at play. The ultimate effect of the
communication initiated by the FGF21 messenger is to elicit ben-
eficial signals from adipocytes that aid in reduction of the effects
of stress and prevention of tissue-specific damage and pathologies
resulting from prolonged stress.
THE ROLE OF ADIPOSE TISSUE IN THE FGF21 STRESS RESPONSE
As a first responder to the SOS message carried by FGF21, how do
adipocytes through FGF21-mediated activation of FGFR1-KLB
aid stressed tissues and in particular liver and muscle? In addition
to as a reservoir of energy, adipose tissue is an endocrine organ
capable of systemic signaling through its lipid metabolites and
adipokines (47, 48). A number of effects of FGF21 on adipose tis-
sue adipocytes have been reported. These include the induction of
expression of nuclear receptors and coactivators, diverse enzymes
and their cytoplasmic regulators involved in pathways for glucose,
lipid, and energy metabolism, and the broad changes in systemic
and local tissue metabolic substrates and control pathways (1, 2, 4,
9, 40, 43).
Two major effects of FGF21 directly on adipose tissue stand
out that may contribute to relief of metabolic stress on liver and
muscle. Activation of the adipocyte FGFR1-KLB complex modu-
lates the rate of adipocyte lipolysis and fatty acid oxidation that
indirectly relieves hepatocyte steatosis or muscular lipid overload.
Upregulation of expression of genes involved in fatty acid oxida-
tion, browning of white fat and thermogenesis is also thought to
collectively contribute to the anti-obesogenic effects (1, 29, 40, 49)
in the obese. In contrast, activation of the adipocyte FGFR1-KLB
complex during starvation dampens the rate of adipocyte lipolysis,
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FIGURE 1 | Fibroblast growth factor 21 as a stress hormone acting via a
tissue-adipocyte communication axis. Stressed tissues through induction
of FGF21 (left box) alert adipocytes by activating the adipocyte FGFR1-KLB
complex (center box). Adipocytes respond with secretory metabolic products
and adipokines that alleviate tissue-specific stress through modification of
cellular pathways whose alterations (right box) are a potentially destructive
result of systemic or internal cellular stress (left box). Systemic FGF21 acts on
adipocytes in major adipose depots or in the microenvironment of peripheral
tissues. Breast is shown as an example of the latter. FGF21-induced
adipocyte secretory products, such as adiponectin, leptin, and free fatty acids
(FFAs), act both systemically or in the local microenvironment (center box) to
affect stressed organs or parenchymal cells, respectively.
which may help to extend energy usage. Secondly, recent studies
show that FGF21 regulates the endocrine function of adipocytes
including the secretion of adipokines that act on diverse tis-
sues throughout the body. Notably the adipokine adiponectin is
upregulated and leptin downregulated by FGF21. They appear
to mediate many of the systemic and local effects of FGF21 (50,
51). Reduction of effects of a lipotoxic environment and oxida-
tive stress is a common feature of adiponectin in liver, muscle,
heart, kidney, pancreas, and endothelium (52). Thus, both the reg-
ulation of fatty acid metabolism and modifications of adipokine
profile by FGF21 are favorable for the relief of liver’s steatotic bur-
den that, when extreme and chronic, causes irreversible hepatic
damage (Figure 1). Similarly, these FGF21-induced adipocyte
responses are favorable for reduction of lipid overload and lipo-
toxicity in stressed or diseased muscle and possibly other tissues
when autophagy/mitophagy, the mitochondria-ER-Golgi network
or homeostasis in insulin function and glucose, lipid, and energy
metabolic networks is compromised (34, 53).
Are adipocytes via the FGFR1-KLB partnership the primary or
even specific target of systemic or local FGF21 signal observed
in diverse body tissues? FGF21-stimulated changes in systemic
metabolites and adipokines whose receptors are distributed widely
have potential to indirectly affect practically all body tissues. More-
over, adipocytes that are characterized by expression of FGFR1-
KLB and present in the microenvironment of most, if not all,
tissues have potential to affect functions of adjacent tissues via
FGF21-controlled paracrine products in the microenvironment.
A careful dissection of both FGFR isotypes and KLB and sig-
nals elicited by the partnership in parenchymal and adipocytes of
diverse organs that show a response to systemic FGF21 is required
to clarify whether non-adipocyte cells constitute additional direct
targets for FGF21. It has been suggested that FGF21 may signal
directly in hepatocytes (54), pancreatic islet beta cells (31, 32), and
cells in the suprachiasmatic nucleus of the hypothalamus and the
dorsal vagal complex of the hindbrain (55, 56).
CONCLUSION AND FUTURE PERSPECTIVE
Since the discovery of the regulatory function of FGF21 in metab-
olism in 2005, studies have focused on the dramatic systemic
pharmacological effects and clinical potential of FGF21 in alle-
viation of obesity and diabetes. These have obscured its general
role as a stress hormone in organ-specific physiopathologies with
adipose tissue as its tissue target and adipocyte FGFR1-KLB as its
molecular target. The adipocyte FGFR1-KLB complex accounts
for the weight reduction and anti-diabetic effects of pharmacolog-
ical FGF21 (40–44). It also likely accounts for the stress-reducing
metabolic effects of FGF21 in tissues undergoing a wide range of
conditions causing systemic metabolic as well as local tissue and
cellular stress. Induced FGF21 expression may be of utility as a
biomarker for these conditions. In addition to obesity and its asso-
ciated metabolic syndromes, pharmacological levels of FGF21 may
be of therapeutic benefit for chronic tissue-specific stress-related
diseases.
One important question is whether the treatment of meta-
bolic abnormalities accompanying obesity and diabetes and the
relief of stress in diverse tissues occur through the same or
overlapping adipocyte signals controlled by FGF21 (Table 1).
The uncoupling of lipolysis and lipogenesis by FGF21-FGFR1-
KLB directly in adipocytes and indirectly in hepatocytes together
with FGF21-stimulated “browning” of fat and thermogenesis have
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Table 1 | Outstanding questions.
How do different stress conditions commonly induce FGF21 expression?
Is FGF21 of biomarker value for tissue stress?
Do the roles of FGF21 in the stress response and treatment of obesity occur through the same mechanisms?
Do tissues/organs other than liver and muscle also utilize FGF21 as a stress signal?
What is the full spectrum of FGF21-controlled adipocyte signals (metabolites and adipokines) that contribute to alleviation of stress?
How does FGF21 direct KLB-FGFR1 kinase signaling to control adipose tissue function instead of mitogenesis?
been suggested to create a state of futile cycling and enhanced
energy expenditure that causes overall reduction of body weight
and systemic lipids in the obese (1, 29, 40, 46, 49). Under the
life-threatening stress of prolonged starvation, this same FGF21-
FGFR1-KLB mediated uncoupling of overall lipid and carbohy-
drate metabolism may serve to stretch out lipid reserves for brain
fuels to preserve consciousness and reduce neural stress for as long
as possible until feeding resumes (9, 46). FGF21-elicited adipocyte
signals appear to commonly alleviate the extent of hepatic steatosis
under the opposite metabolic extremes of obesity and starva-
tion, and the muscular metabolic stress associated with autophagic
defects and mitochondrial respiratory dysfunction.
Adipokines have emerged as FGF21-induced endocrine signals
that also communicate back to stressed tissues. The upregulation
of adiponectin currently is in the spotlight (40, 50, 51) although the
role of the full spectrum of FGF21-controlled adipokines deserves
investigation (Table 1). The many facets of the roles of FGF21 as
a stress hormone that recruits the aid of adipose tissue adipocytes
and its ramifications for stress-related diseases promise to be a
broad and fruitful field of future study.
In addition to the tissue-specific responses to FGF21-
stimulated adipocyte signals that alter metabolism to reduce tissue
stress, the mechanisms that control the induction of FGF21 in spe-
cific tissues in crisis also requires clarification (Table 1). Multiple
transcription factors including nuclear receptors have been impli-
cated in control of FGF21 expression in different tissues. Some of
them are involved in the intrinsic cellular stress-responsive path-
ways, such as the SREBP1c and ATF4 in the ER stress response
that are associated with the Golgi, peroxisome (53, 57), and mito-
chondria and involved in lipid, energy, and glucose metabolism.
Future studies may reveal novel tissue-specific FGF21-mediated
stress response pathways and mechanisms.
The overarching canonical role of members of the diverse
FGF superfamily in the adult is coordination of tissue homeosta-
sis through autocrine and paracrine growth-promoting signaling
controlled by matrix heparan sulfate. With the loss of affinity for
heparan sulfate and gain of selectivity for the FGFR1-KLB com-
plex that predominates in mature adipocytes, FGF21 has evolved
as an inter-organ stress signal to adipocytes for negative reg-
ulation of systemic and cellular metabolic stress. This concept
may also apply to evolution of other endocrine FGFs referred
to as the FGF19 subfamily. The inter-organ crosstalk between
ileal FGF19 and liver FGFR4-KLB is a negative regulatory mecha-
nism of postprandial bile acid levels serving to prevent stress and
damage resulting from exposure to prolonged and elevated lev-
els of bile acids (58). Similarly, the negative regulation of mineral
re-absorption levels signaled by the crosstalk between bone FGF23
and kidney FGFR1-KL (59) may limit potential stress and damage
from mineral overload. The effects of the FGF19 subfamily are
pleiotropic and complex on both local tissue and organism levels.
Detailed dissection of the action of each endocrine FGF in inter-
organ or cross-tissue communication and stress relief promises to
be a novel conceptual base for pursuit of complete understanding
of the biology of endocrine FGFs.
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